{
    "clinical_study": {
        "@rank": "58907", 
        "brief_summary": {
            "textblock": "To investigate the toxicity of interferon alfa-2b ( IFN alfa-2b ) in combination with\n      nucleoside analog therapy in HIV-positive patients with chronic hepatitis C. To determine\n      the efficacy of treatment with IFN alfa-2b for chronic hepatitis C in patients with advanced\n      HIV infections treated with nucleoside analog therapy.\n\n      IFN alfa-2b has HIV inhibitory properties and has also been approved for treatment of\n      chronic hepatitis C. Studies have shown that IFN alfa-2b is effective in asymptomatic\n      HIV-positive patients with chronic hepatitis C, but the drug's benefit against hepatitis C\n      in patients with advanced HIV infection has not been determined."
        }, 
        "brief_title": "The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections", 
        "completion_date": {
            "#text": "September 1996", 
            "@type": "Actual"
        }, 
        "condition": [
            "HIV Infections", 
            "Hepatitis C"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "IFN alfa-2b has HIV inhibitory properties and has also been approved for treatment of\n      chronic hepatitis C. Studies have shown that IFN alfa-2b is effective in asymptomatic\n      HIV-positive patients with chronic hepatitis C, but the drug's benefit against hepatitis C\n      in patients with advanced HIV infection has not been determined.\n\n      Patients receive interferon alpha-2b subcutaneously 3 times weekly for 6 months. If no\n      response is seen after 18 weeks of therapy or if an initial response is followed by relapse\n      while on therapy, dose is increased. Patients who require a dose escalation should continue\n      on IFN alfa-2b for an additional 6 months. All patients will also receive available\n      nucleoside analog therapy ( zidovudine, didanosine, zalcitabine ) at currently accepted\n      doses as clinically appropriate."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Treatment or suppression of opportunistic infections with standard drugs.\n\n          -  Pneumovax, HIB, tetanus, influenza, and hepatitis B vaccines.\n\n          -  Clinically indicated antibiotics.\n\n          -  Short courses of steroids (< 21 days) for acute problems not related to hepatitis C.\n\n          -  Other regularly prescribed medications such as analgesics, nonsteroidal\n             anti-inflammatory agents, antipyretics, allergy medications, and oral contraceptives.\n\n        Patients must have:\n\n          -  HIV positivity.\n\n          -  Documented hepatitis C virus.\n\n          -  CD4 count <= 200 cells/mm3.\n\n          -  No severe liver disease (Grade C Childs-Pugh classification) or chronic liver disease\n             not caused by hepatitis C.\n\n          -  Willingness to be followed for the duration of treatment and follow-up period.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior AZT, ddI, and ddC.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Hepatitis B (HBsAg positive).\n\n          -  Autoimmune hepatitis (FANA titer >= 1:160 and anti-smooth muscle antibody titer >=\n             1:160).\n\n          -  Wilson's disease.\n\n          -  alpha-1 antitrypsin deficiency.\n\n          -  Hemochromatosis.\n\n          -  Malignancy requiring systemic chemotherapy.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Nonnucleoside analog therapy for HIV.\n\n          -  Biologic response modifiers.\n\n          -  Systemic cytotoxic chemotherapy.\n\n          -  Chronic systemic steroid use.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy other than local irradiation to the skin.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prednisone within 12 weeks prior to study entry (if patient has received prior daily\n             doses for 1 month or longer duration).\n\n          -  Acute therapy for an infection within 2 weeks prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "10", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001035", 
            "org_study_id": "ACTG 203P", 
            "secondary_id": "11180"
        }, 
        "intervention": [
            {
                "intervention_name": "Interferon alfa-2b", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zalcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Zalcitabine", 
                "Didanosine", 
                "Interferon Alfa-2b", 
                "Interferons", 
                "Zidovudine", 
                "Reaferon"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Interferon Alfa-2b", 
            "Zalcitabine", 
            "Didanosine", 
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "Zidovudine", 
            "Hepatitis C"
        ], 
        "lastchanged_date": "April 27, 2012", 
        "link": [
            {
                "description": "Click here for more information about Zidovudine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
            }, 
            {
                "description": "Click here for more information about Didanosine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=16"
            }, 
            {
                "description": "Click here for more information about Interferon alfa-2", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=34"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "USC CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "462025250"
                    }, 
                    "name": "Indiana Univ. School of Medicine, Infectious Disease Research Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NY Univ. HIV/AIDS CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Pilot Study of the Safety and Efficacy of Interferon Alfa-2b (IFN Alfa-2b) in Combination With Nucleoside Analog Therapy in Patients With Combined Hepatitis C (HCV) and Advanced Human Immunodeficiency Virus (HIV) Infections", 
        "overall_official": [
            {
                "last_name": "Gill JC", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Eyster ME", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001035"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": {
                "agency": "Schering-Plough", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "Indiana Univ. School of Medicine, Infectious Disease Research Clinic": "39.769 -86.158", 
        "NY Univ. HIV/AIDS CRS": "40.714 -74.006", 
        "USC CRS": "34.052 -118.244"
    }
}